CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022

Rhea-AI Summary

CASI Pharmaceuticals (Nasdaq: CASI) will host a conference call on August 12, 2022, at 8:00 A.M. EST to discuss its second quarter financial results. The call will feature updates from the Chairman & CEO concerning the company's business and milestones. Investors can join the call by dialing specific numbers provided in the announcement. CASI Pharmaceuticals specializes in developing innovative therapeutics and pharmaceutical products in China and the U.S., focusing on hematology and oncology.

Positive

• CASI Pharmaceuticals is focused on developing innovative therapeutics, indicating potential for future growth.
• The company has established a strong sales and marketing team in China with over 100 specialists.

Negative

• None.

ROCKVILLE, Md. and BEIJING, Aug. 5, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the financial results for the second quarter of 2022, at 8:00 A.M. EST on Friday, August 12^th, 2022.

On the call, CASI's Chairman & CEO will provide an update on the Company's business and upcoming milestones. The conference call can be accessed by dialing 1-866-218-2402 (U.S.) or 1-412-902-6605 (International) and ask to be joined into the CASI Pharmaceuticals call to listen to the live conference call. Confirmation #10169302.

This call will be recorded and available for replay by dialing 1-877-344-7529 (U.S.) or 1-412-317-0088 (International) and enter 9173539 to access the replay.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT: Rui Zhang CASI Pharmaceuticals, Inc. 240.864.2643 ir@casipharmaceuticals.com

INVESTOR CONTACT: Xuan Yang Solebury Trout 646.378.2975 xyang@soleburytrout.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-report-second-quarter-2022-financial-results-and-host-conference-call-august-12-2022-301600771.html

SOURCE CASI Pharmaceuticals, Inc.

FAQ

When will CASI Pharmaceuticals report its second quarter financial results?

CASI Pharmaceuticals will report its second quarter financial results on August 12, 2022.

How can I access the CASI Pharmaceuticals conference call?

You can access the CASI Pharmaceuticals conference call by dialing 1-866-218-2402 (U.S.) or 1-412-902-6605 (International).

What is the main focus of CASI Pharmaceuticals?

CASI Pharmaceuticals focuses on developing and commercializing innovative therapeutics, particularly in hematology and oncology.

Who will be providing updates during the conference call?

The updates during the conference call will be provided by CASI's Chairman & CEO.